keyboard_arrow_up

Global Dermatophytic Onychomycosis Market Analysis and Forecast Report 2020

SandlerResearch.org adds Global Dermatophytic Onychomycosis Market 2016-2020 a new research reports in its store. The analysts forecast global Dermatophytic Onychomycosis market to grow at a CAGR of 7.44% during the period 2016-2020.

Commenting on the report, an analyst said: "It has been found that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. For instance, a combination of amorolfine nail lacquer and oral terbinafine, the most commonly used combination therapy, has improved clinical efficiency and is more cost-effective than terbinafine alone. At times, the combination of surgery and systemic and topical therapies are also used. Sometimes, non-pharmacological approaches such as laser or mechanical treatment are also used in combination with topical and systemic therapy. Such trends will have a positive impact on the growth of the market."

 

According to the report, the increase in R&D to develop drugs with disease-modifying properties and a better safety and efficacy profile drives the market.

For more information Inquire @ http://www.sandlerresearch.org/inquire-before-buying?rname=51777

Further, the report states that the side effects associated with dermatophytic onychomycosis drugs are a challenge to the market as they hamper the acceptance of advanced drugs to treat moderate to severe dermatophytic onychomycosis.

Top vendors are Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis and Valeant Pharmaceuticals

Other Prominent Vendors in the market are: Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals and Viamet Pharmaceuticals.

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the

Key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

What are the strengths and weaknesses of the key vendors?

What are the strengths and weaknesses of the key vendors? Purchase report directly @ http://www.sandlerresearch.org/purchase?rname=51777  Single user copy USD2500

Table of Content for Global Dermatophytic Onychomycosis Market 2016-2020:

PART 01: Executive summary

Highlights

 

PART 02: Scope of the report

Market overview

Product offerings

 

PART 03: Market research methodology

Research methodology

Economic indicators

 

PART 04: Introduction

Key market highlights

Key buying criteria

 

PART 05: Overview: Dermatophytic onychomycosis

Types of dermatophytic onychomycosis

Risk factors

Management

Epidemiology

 

PART 06: Pipeline analysis

TDT 067

P-3058

MOB-015

VT-1161

Luliconazole solution, 10%

ME1111

NP213

HXP124

 

PART 07: Market landscape

Market overview

Market size and forecast

Five forces analysis

 

PART 08: Market segmentation by route of administration

Topical

Oral

 

PART 09: Geographical segmentation

Global dermatophytic onychomycosis market by geographical segmentation 2015-2020

Dermatophytic onychomycosis market in Americas

Dermatophytic onychomycosis market in EMEA

Dermatophytic onychomycosis market in APAC

 

PART 10: Market drivers

Increase in R&D

Growing prevalence of dermatophytic onychomycosis

Unmet medical needs

Rise in prevalence of diabetes

 

PART 11: Impact of drivers

 

PART 12: Market challenges

Adverse effects and limited efficacy of drugs

Lack of awareness

Increased availability of generics and alternative therapies

Product recalls by US FDA

 

PART 13: Impact of drivers and challenges

 

PART 14: Market trends

Increased focus on combination therapies

Outsourcing of drugs manufacturing

Increase in strategic alliances among vendors

Incorporation of novel technology for product development

 

PART 15: Vendor landscape

Competitive scenario

Anacor Pharmaceuticals

Galderma

Janssen Biotech

Novartis

Valeant Pharmaceuticals

Other prominent vendors

 

PART 16: Appendix

List of abbreviations

 

List of Exhibits

Exhibit 01: Key buying criteria for dermatophytic onychomycosis drugs

Exhibit 02: Percentage of population undergoing treatment globally 2015

Exhibit 03: Pharmacological treatment for dermatophytic onychomycosis

Exhibit 04: Treatment algorithm for dermatophytic onychomycosis

Exhibit 05: Global dermatophytic onychomycosis therapeutics market overview

Exhibit 06: Global dermatophytic onychomycosis market 2015-2020 ($ billions)

Exhibit 07: Five forces analysis

Exhibit 08: Comparison of activity of topical medications for onychomycosis

Exhibit 09: Comparison of activity of oral medications for onychomycosis

Exhibit 10: Global dermatophytic onychomycosis market segmentation by route of administration based on volume 2015

Exhibit 11: Dermatophytic onychomycosis market in US by route of administration based on revenue 2015

Exhibit 12: Segmentation of global dermatophytic onychomycosis market based on geography 2015

Exhibit 13: Global dermatophytic onychomycosis market revenue by geography 2015-2020 ($ billions)

Exhibit 14: Dermatophytic onychomycosis market in Americas 2015-2020 ($ billions)

Exhibit 15: Dermatophytic onychomycosis market in EMEA 2015-2020 ($ billions)

Exhibit 16: Dermatophytic onychomycosis market in APAC 2015-2020 ($ billions)

Exhibit 17: Global dermatophytic onychomycosis market: YoY growth and revenue based on geography 2015-2020

Exhibit 18: Comparison of onychomycosis prevalence with major diseases in US 2013

Exhibit 19: Impact of drivers

Exhibit 20: Impact of drivers and challenges

Exhibit 21: Anacor Pharmaceuticals: Key takeaways

Exhibit 22: Galderma: Key takeaways

Exhibit 23: Janssen Biotech: Key takeaways

Exhibit 24: Novartis: Key takeaways

Exhibit 25: Valeant Pharmaceuticals: Key takeaways

And more.

Complete report available at http://www.sandlerresearch.org/global-dermatophytic-onychomycosis-market-2016-2020.html

About US:     

Sandlerresearch.org is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.